Bioptigen has received 510(k) clearance from the FDA to begin marketing its hand-held spectral-domain
optical coherence tomography (OCT) device (Envisu) for use in patients.
Author: ModernMedecine
Achieve meaningful use of your electronic health record
Adoption of electronic health record technology has been slow, particularly among
ophthalmologists.
On the road to optical precision
The corrections following phacoemulsification and IOL implantation that are achievable today are a far
cry from those commanded in the 1970s when 20/40 corrected bilaterally was considered an accomplishment following
implantation of the early I…
Secrets you don’t know about your staff
Losing staff is a devastating experience.
FDA Oks new inidication for iFS femtosecond laser
On April 20, Abbott Medical Optics announced that it had received FDA clearance for use of the 150-kHz
iFS advanced femtosecond laser to create arcuate incisions during corneal surgery, including cataract
surgery.
Protection an elusive goal
Many agents have been investigated in clinical trials for neuroprotection in glaucoma, but none has
proven efficacy, and so IOP control continues to be the mainstay strategy for preventing glaucoma
progression.
Quandary: wave-front guided with low higher-order aberrations?
Leading refractive surgeons agree wavefront-guided ablation is a significant advance in laser vision
correction, but have different opinions about its role in treating myopic eyes with low higher-order
aberrations.
Agent useful for uveitic cystoid macular edema
Using interferon alpha-2b systemically for the treatment of refractory uveitic cystoid macular edema
may be helpful in carefully selected patients.
Eye-care professionals still slow to adopt electronic health records
Independent medical practices continue to adopt electronic health record technology at an increasing
rate.
Radiation lowers treatment burden
Epimacular brachytherapy was described as "interesting and encouraging" at the 2-year
time point for treating exudative age-related macular degeneration that had been previously treated with
anti-vascular endothelial growth factor injec…
American Societry of Cataract and Refractive Surgery exchange
As outgoing president of the ASCRS, Edward J. Holland, MD, can be recognized for a number of
accomplishments and the introduction of several new initiatives.
Updates from ARVO 2012
The Association for Research in Vision and Ophthalmology closed its 2012 annual meeting with more than
12,500 participants – its largest attendance ever.
A place in the sun
The premium sunglasses business is very trendy.
Etiology determines intraocular pressure treatment
Understanding the cause of elevated IOP in patients with uveitis is the basis for developing a
rational treatment plan.
New technology triumphs
As a rule, the latest and greatest new technology first becomes available to the haves in this world,
and only much later, if at all, to the have-nots.
All eyes on Capitol Hill
A record number of ophthalmologists hit the hallways on Capitol Hill last month to urge their
legislators to protect Americans’ access to eye care and boost funding for eye research.
VEGF Trap-Eye improves vision in diabetic eye disease
NEW YORK (Reuters Health) -Vascular Endothelial Growth Factor (VEGF) Trap-Eye provided a significant
benefit to patients with diabetic macular edema in a phase II trial – and updated data now shows the initial
improvements were sustained or inc…
Topical antibiotics boost risk of endophthalmitis after eye injections
NEW YORK (Reuters Health) – After intravitreal injections of anti-vascular endothelial growth factors
or triamcinolone, topical antibiotics might actually be unhelpful, a new paper suggests.
Vitamins E, C no help against macular degeneration
NEW YORK (Reuters Health) – Taking vitamins E and C may do nothing to protect aging eyes from macular
degeneration, in the longest-running one to test vitamin E for eyesight in men, and the first to test vitamin C
alone.
Adalimumab improves refractory uveitis
NEW YORK (Reuters Health) – Subcutaneous injections of adalimumab may decrease steroid requirements in
patients with refractory uveitis, according to Spanish researchers.